Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável / Use of probiotics in the treatment of patients with irritable bowel syndrome
Abstract
INTRODUÇÃO: A Síndrome do Intestino Irritável (SII) é um dos distúrbios funcionais mais comuns do sistema gastrointestinal e diferenças na composição da microbiota luminal de pacientes com SII foram observadas em grande parte dos níveis taxonômicos bacterianos. Portanto, a utilização de probióticos é considerada uma terapia alternativa e coadjuvante no tratamento. METODOLOGIA: Trata-se de um estudo qualitativo de revisão narrativa, no qual foram utilizadas as bases de dados PubMed, Google Scholar, Cochrane Library, EMBASE, MedLine, Scopus e Clinicaltrial.gov. Os descritores encontrados no DeCS e Emtree foram os seguintes: “terapia”, “síndrome do intestino irritável” e “probióticos”, tendo sido selecionados 24 artigos. RESULTADOS: A maioria dos resultados são promissores, porém não é possível definir com precisão qual probiótico ou qual associação de probióticos é eficaz, bem como qual é a dose e a duração do tratamento. DISCUSSÃO: Diversos estudos apontam os efeitos benéficos do uso da combinação de probióticos em pacientes com SII, mesmo que o mecanismo de ação desses microrganismos no alívio dos sintomas continue incerto. CONCLUSÃO: É necessária a realização de maior número de ensaios clínicos randomizados, a fim de determinar quais linhagens bacterianas, concentrações e duração do tratamento são mais efetivas na abordagem dos pacientes.
Keywords
Full Text:
PDF (Português (Brasil))References
CATINEAN, A. et al. Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome. Nutrients, [S.L.], v. 11, n. 9, p. 1968, 21 ago. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11091968.
CHONG. P. P.; CHIN, V. K.; LOOI, C.Y.; WONG, W. F.; MADHAVAN, P.; YONG, V. C. The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol. 2019; 10:1136. https://pubmed.ncbi.nlm.nih.gov/31244784/
DALE, H. F. et al. Probiotics in Irritable Bowel Syndrome: an up-to-date systematic review. Nutrients, [S.L.], v. 11, n. 9, p. 2048, 2 set. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11092048.
DIDARI, T. et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World Journal Of Gastroenterology, [S.L.], v. 21, n. 10, p. 3072-3084, 14 mar. 2015. Baishideng Publishing Group Inc. http://dx.doi.org/10.3748/wjg.v21.i10.3072.
FORD, A. C. et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, [S.L.], v. 48, n. 10, p. 1044-1060, 8 out. 2018. Wiley. http://dx.doi.org/10.1111/apt.15001.
HAN, K. et al. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. Journal Of Gastroenterology, [S.L.], v. 52, n. 4, p. 432-443, 13 maio 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s00535-016-1224-y.
HARPER, A. et al. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. Foods, [S.L.], v. 7, n. 2, p. 13, 26 jan. 2018. MDPI AG. http://dx.doi.org/10.3390/foods7020013.
KAJANDER, K. et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics, [S.L.], v. 27, n. 1, p. 48-57, 5 out. 2007. Wiley. http://dx.doi.org/10.1111/j.1365-2036.2007.03542.x.
KONTUREK, P. C. et al. Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom. Mmw - Fortschritte Der Medizin, [S.L.], v. 159, n. 7, p. 1-5, 4 dez. 2017. Springer Science and Business Media LLC. https://doi.org/10.1007/s15006-017-0338-3.
LIANG, D. et al. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine, [S.L.], v. 98, n. 27, p. 16068, jul. 2019. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/md.0000000000016068.
LYRA, A. et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World Journal Of Gastroenterology, [S.L.], v. 22, n. 48, p. 10631, 28 dez. 2016. Baishideng Publishing Group Inc. http://dx.doi.org/10.3748/wjg.v22.i48.10631.
MEZZASALMA, V. et al. A Randomized, Double-Blind, Placebo-Controlled Trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. Biomed Research International, [S.L.], v. 2016, p. 1-10, 9 ago. 2016. Hindawi Limited. http://dx.doi.org/10.1155/2016/4740907.
OH, J. H. et al. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, [S.L.], v. 11, n. 12, p. 2887, 27 nov. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11122887.
OOI, S. L. et al. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome – What is the current evidence? Complementary Therapies In Medicine, [S.L.], v. 43, p. 73-80, abr. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.ctim.2019.01.010.
PRESTON, K. et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Beneficial Microbes, [S.L.], v. 9, n. 5, p. 697-706, 11 jun. 2018. Wageningen Academic Publishers. http://dx.doi.org/10.3920/bm2017.0105.
PRINCIPI, N. et al. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. Journal Of Infection, [S.L.], v. 76, n. 2, p. 111-120, 29 dez. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.jinf.2017.12.013.
PUSCEDDU, M. M. et al. Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics. Current Pathobiology Reports, [S.L.], v. 6, n. 1, p. 1-13, 12 fev. 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40139-018-0160-3.
SISSON, G. et al. Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study. Alimentary Pharmacology & Therapeutics, [S.L.], v. 40, n. 1, p. 51-62, 11 maio 2014. Wiley. http://dx.doi.org/10.1111/apt.12787.
SPILLER, R. et al. Review article: probiotics and prebiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, [S.L.], v. 28, n. 4, p. 385-396, 4 jun. 2008. Wiley. http://dx.doi.org/10.1111/j.1365-2036.2008.03750.x.
STAUDACHER, H. M. et al. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low fodmap diet. Proceedings Of The Nutrition Society, [S.L.], v. 75, n. 3, p. 306-318, 24 fev. 2016. Cambridge University Press (CUP). http://dx.doi.org/10.1017/s0029665116000021.
SUN, J. R. et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. The Saudi Journal Of Gastroenterology, [S.L.], p. 66-77, 2019. Medknow. http://dx.doi.org/10.4103/sjg.sjg_384_19.
WEN, Y. et al. The efficacy and safety of probiotics for patients with constipationpredominant irritable bowel syndrome: A systematic review and metaanalysis based on seventeen randomized controlled trials. International Journal Of Surgery, [S.L.], v. 79, p. 111-119, jul. 2020. Elsevier BV. http://dx.doi.org/10.1016/j.ijsu.2020.04.063.
YUAN, F. et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research And Opinion, [S.L.], v. 33, n. 7, p. 1191-1197, 7 mar. 2017. Informa UK Limited. http://dx.doi.org/10.1080/03007995.2017.1292230.
ZHANG, Y. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. Bmc Gastroenterology, [S.L.], v. 16, n. 1, p. 1-11, 13 jun. 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12876-016-0470-z.
DOI: https://doi.org/10.34119/bjhrv3n4-358
Refbacks
- There are currently no refbacks.